Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 3/20 | 0.46 |
| ▸ | ERBB2 | P04626 | 2/20 | 0.46 |
| ▸ | ERBB3 | P21860 | 2/20 | 0.46 |
| ▸ | KDR | P35968 | 2/20 | 0.46 |
| ▸ | PTK2 | Q05397 | 2/20 | 0.46 |
| ▸ | MTNR1A | P48039 | 2/20 | 0.41 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.40 |
| ▸ | MMP2 | P08253 | 1/20 | 0.40 |
| ▸ | MMP9 | P14780 | 1/20 | 0.40 |
| ▸ | HTR6 | P50406 | 1/20 | 0.39 |
| ▸ | CHRNB1 | P11230 | 1/20 | 0.39 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.39 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.39 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.39 |
| ▸ | CHRNB3 | Q05901 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7568479 | 0.93 | MMP2 (0.43) | EGFRERBB2ERBB3KDRPTK2 | |
| SCHEMBL9325734 | 0.90 | MTNR1A (0.50) | MTNR1AMTNR1BCHRNB4CHRNA3 | |
| SCHEMBL6313386 | 0.80 | MTNR1A (0.46) | EGFRERBB2ERBB3KDRPTK2 | |
| SCHEMBL7572411 | 0.78 | CHRNB2 (0.40) | CHRNB2CHRNB4CHRNA3 | |
| SCHEMBL7812867 | 0.77 | CHRNB2 (0.52) | EGFRERBB2CHRNB2CHRNB4CHRNA3 | |
| SCHEMBL6308711 | 0.74 | USP2 (0.47) | MTNR1A | |
| SCHEMBL7571886 | 0.74 | CHRNB2 (0.44) | CHRNB2CHRNB4CHRNA3 | |
| SCHEMBL21590257 | 0.73 | CHRNB4 (0.45) | CHRNB4CHRNA3 | |
| SCHEMBL6314991 | 0.72 | HTR1A (0.64) | MTNR1B | |
| SCHEMBL12090214 | 0.71 | CHRNA7 (0.56) | CHRNB2CHRNB4CHRNA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020058811-A1 | Naphthalene derivatives | CHENARD BERTRAND L (US) | 2002-05-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020058811-A1 | Naphthalene derivatives | HTR4, CNR1, CNR2 | EGFR 1635/4885ERBB2 2282/4885ERBB3 2330/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.